Eli Lilly Stock Falls After Release of New Alzheimer's Drug Data (NYSE: LLY)

The Eli Lilly stock price fell as much as 4.8% this morning (Wednesday) after the company released new trial results on its Alzheimer's drug solanezumab.

Eli Lilly and Co. (NYSE: LLY) officials released data from a follow-up study on two of the drug's earlier trials. The Alzheimer's drug fell short of its goals in the first two trials, but the new data showed encouraging signs.

Here's everything investors need to know now...

Tags: Eli Lilly Alzheimer's, Eli Lilly stock, Eli Lilly stock...

What feeling does this article give you?

#hashtags to follow:

Eli Lilly [+]    Alzheimer [+]    NYSE [+]    LLY [+]    Tags [+]    Eli Lilly Alzheimer [+]   

More #news: